Mont-Saint-Guibert, Belgium \u2013 September 5, 2024, 10:30pm CET \/ 4:30pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/strong>\u00a0(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in three upcoming investor conferences in New York City.<\/p>\n Olivier Taelman, Nyxoah\u2019s Chief Executive Officer, will deliver corporate updates at the Baird Global Healthcare Conference on Tuesday, September 10, 2024, at 12:15pm ET, the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024, at 11:00am ET and the Cantor Global Healthcare Conference on Wednesday, September 18, 2024 at 1:55pm ET. Webcasts of the presentations will be available on the\u00a0Events section<\/a>\u00a0of Nyxoah\u2019s Investor Relations website. The Company will also be available for 1×1 meetings with institutional investors attending the events.<\/p>\n Nyxoah\u2019s Investor Presentation can be accessed on the\u00a0Shareholder Information<\/a>\u00a0section of the Company\u2019s Investor Relations page.<\/p>\n About Nyxoah<\/strong><\/p>\n Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah\u2019s lead solution is the Genio\u00ae system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world\u2019s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.<\/p>\n For more information, please see the Company\u2019s annual report for the financial year 2023 and visit\u00a0http:\/\/www.nyxoah.com\/<\/a>.<\/p>\n Caution\u00a0<\/strong>\u2013 CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.<\/p>\n Forward-looking statements<\/strong><\/p>\n Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company\u2019s or, as appropriate, the Company directors\u2019 or managements\u2019 current expectations regarding the entry into of the loan facility agreement and the synthetic warrant agreement with the EIB; the use of proceeds from the loan facility agreement; the Genio\u00ae system and ongoing clinical studies of the Genio\u00ae system; the potential advantages of the Genio\u00ae system; Nyxoah\u2019s goals with respect to the development, regulatory pathway and potential use of the Genio\u00ae system; the utility of clinical data in potentially obtaining FDA approval of the Genio\u00ae system; reporting data from Nyxoah\u2019s DREAM U.S. pivotal trial; filing for FDA approval; and entrance to the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.<\/p>\n Contacts:<\/strong><\/p>\n Nyxoah<\/strong> For Media<\/strong> International\/Germany Attachment<\/strong><\/p>\n
\nLo\u00efc Moreau, Chief Financial Officer
\nIR@nyxoah.com<\/a><\/p>\n
\nBelgium\/France
\nBackstage Communication \u2013 Gunther De Backer
\ngunther@backstagecom.be<\/a><\/p>\n
\nMC Services \u2013 Anne Hennecke
\nnyxoah@mc-services.eu<\/a><\/p>\n
![](\"https:\/\/ml-eu.globenewswire.com\/media\/MmU0OGNmYTgtMmU0MS00NjAyLWJkMDYtNzdhZmJmMjI1OWNmLTEyMDkxODA=\/tiny\/Nyxoah.png\")
<\/p>\n